Perrigo launches generic Zaditor
This article was originally published in The Tan Sheet
Executive Summary
Perrigo ships its generic of Novartis Pharmaceuticals' Zaditor, a ketotifen fumarate ophthalmic solution, .025 percent, the Allegan, Mich.-based private labeler says in a March 15 release. Perrigo CEO Joseph Papa said the firm is "excited to launch into a new adjacent OTC category, ophthalmics." Zaditor is a solution used to temporarily prevent allergic conjunctivitis. Wolters Kluwer data estimates the annual sales of Zaditor in the last 12 months reached $15 million, Perrigo said. Competition in the eye-care market increased with the recent launch of Johnson & Johnson/McNeil's Zyrtec Allergy Eye Relief Drops and Schering-Plough's Claritin Eye, which also contain ketotifen fumarate as the active ingredient (1"The Tan Sheet" Jan. 11, 2010)
You may also be interested in...
Zyrtec and Claritin Eye Drops Use Different Tactics In Head To Head Fight
Thanks to a multi-media blitz, McNeil's Zyrtec Allergy Eye Relief Drops secured nearly twice the market share as a Claritin product from Schering-Plough with the same active drug that launched at the same time in summer 2009
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.